V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20062129 | 20157574 | 1.77 | 48 | Neo-adjuvant (N) | 2020-10-17 | 2021-07-22 | null | N | null | ABIRATERONE | 100436061 |
| 20062389 | 20157576 | 1.93 | null | Palliative (P) | 2020-01-25 | 2020-01-25 | null | N | Y | EVEROLIMUS | 100414109 |
| 20062544 | 20157577 | 1.01 | 95.91 | null | 2018-02-03 | 2018-02-10 | null | 02 | null | TRIFLURIDINE + TIPIRACIL | 101467938 |
| 20062575 | 20157578 | null | null | null | 2019-02-28 | 2019-03-01 | null | 02 | null | BEVACIZUMAB | 101348017 |
| 20062614 | 20157579 | 1.7 | 86.1 | Neo-adjuvant (N) | 2022-04-03 | 2022-04-09 | null | N | N | PEMBROLIZUMAB | 101647803 |
| 20062872 | 20157580 | 1.68 | 70.4 | null | 2021-11-02 | 2021-11-10 | null | 02 | null | CARBOPLATIN + FLUOROURACIL | 101403551 |
| 20063021 | 20157581 | 1.48 | 59 | Curative (C) | null | 2018-02-20 | null | 02 | Y | OXALIPLATIN | 100357790 |
| 20063028 | 20157582 | 1.75 | 85.6 | Neo-adjuvant (N) | 2017-11-04 | 2017-11-04 | null | 02 | N | OXALIPLATIN | 100128107 |
| 20063247 | 20157583 | null | 78 | Adjuvant (A) | 2020-01-15 | 2020-02-02 | null | N | Y | PEMBROLIZUMAB | 100648344 |
| 20063478 | 20157584 | 1.72 | 80.2 | Curative (C) | 2016-11-16 | 2016-11-18 | CAPECITABINE + LOMUSTINE | 02 | null | ARISTOTLE TRIAL | 100756910 |
| 20063535 | 20157585 | null | 71 | 03 | 2019-12-17 | 2020-10-12 | Carboplatin + Pemetrexed | null | N | EPIRUBICIN | 101050887 |
| 20063629 | 20157586 | 1.57 | 75 | null | 2021-01-07 | 2021-03-20 | VDC | 02 | N | OXALIPLATIN + MDG + PANITUMUMAB | 101427593 |
| 20063709 | 20157587 | 1.79 | 70.8 | Palliative (P) | 2019-06-29 | 2019-08-21 | OXALIPLATIN + MDG + PANITUMUMAB | 2 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100147996 |
| 20063853 | 20157588 | 1.74 | 79.6 | null | 2016-01-22 | 2016-01-24 | IRINOTECAN + MDG + PANITUMUMAB | 02 | null | ATEZOLIZUMAB | 101153977 |
| 20063925 | 20157589 | 1.69 | 50 | Palliative (P) | null | 2020-11-09 | BCG Intravesical | 02 | N | MITOMYCIN | 101772865 |
| 20064153 | 20157591 | 1.64 | 44.9 | null | 2020-06-12 | 2020-06-22 | Topotecan (oral) | 02 | null | CAPECITABINE + DOCETAXEL | 100378089 |
| 20064341 | 20157592 | 1.71 | 92.2 | null | 2018-09-07 | 2018-09-07 | Carboplatin + Pemetrexed | 02 | N | NINTEDANIB | 101664633 |
| 20064385 | 20157593 | null | null | 03 | 2017-07-27 | 2017-07-27 | Gemcitabine + Oxaliplatin | 02 | N | ESPAC TRIAL | 101207198 |
| 20064427 | 20157594 | 1.56 | 53.1 | Palliative (P) | 2018-07-29 | 2018-08-13 | Carboplatin + Vinorelbine Oral | 02 | N | GEMCITABINE + OXALIPLATIN | 101817598 |
| 20064608 | 20157595 | 1.75 | 72.6 | null | 2019-12-23 | 2020-01-10 | CISPLATIN + FLUOROURACIL + RT | 02 | N | EPIRUBICIN + ETOPOSIDE + IFOSFAMIDE | 101795504 |
| 20065194 | 20157596 | 1.7 | 68 | null | 2020-04-03 | 2020-04-17 | Ripretinib | 02 | N | BEVACIZUMAB + FLUOROURACIL + IRINOTECAN | 100836554 |
| 20065230 | 20157597 | 1.71 | 67 | Palliative (P) | null | 2021-04-24 | TEMOZOLOMIDE | N | N | BRENTUXIMAB | 101587740 |
| 20065308 | 20157598 | 0 | 57 | null | 2019-06-22 | 2020-01-02 | Hepatoblastoma Relapse VI | 02 | N | RUCAPARIB | 100424129 |
| 20065474 | 20157599 | 1.8 | 76.8 | Adjuvant (A) | null | 2020-11-25 | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | null | null | BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB | 100647715 |
| 20065554 | 20157600 | 1.87 | 18.9 | Palliative (P) | 2017-05-30 | 2017-06-06 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | CAPECITABINE + IRINOTECAN + PANITUMUMAB | 100051064 |
| 20065637 | 20157601 | 1.8 | 75 | null | null | 2019-09-03 | CYCLOPHOSPHAMIDE + RITUXIMAB + Dexamethasone | null | N | OXALIPLATIN + MDG + PANITUMUMAB | 100222094 |
| 20065801 | 20157602 | 1.69 | 58.65 | Palliative (P) | 2020-08-24 | 2020-09-19 | COSMIC TRIAL | 01 | N | CAPECITABINE + TRASTUZUMAB | 101841107 |
| 20065823 | 20157603 | 1.66 | 73 | Neo-adjuvant (N) | 2020-01-25 | 2020-02-07 | Olaparib | Y | Y | ERIBULIN | 100850182 |
| 20065973 | 20157604 | 1.53 | null | Adjuvant (A) | 2016-12-10 | 2016-12-10 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | N | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 101023012 |
| 20066065 | 20157605 | 1.48 | 77.1 | Palliative (P) | 2016-02-26 | 2020-04-25 | EEF or EOF | 02 | N | BENDAMUSTINE + RITUXIMAB | 101436996 |
| 20066336 | 20157607 | 1.79 | 84 | Palliative (P) | 2020-02-03 | 2020-02-17 | Doxorubicin + Steptozotocin | 02 | N | PEMETREXED | 100683337 |
| 20066426 | 20157608 | 1.87 | 67.9 | Adjuvant (A) | 2021-11-27 | 2021-12-01 | TEYSUNO | N | N | SCOPE2 TRIAL | 101338415 |
| 20066495 | 20157609 | 1.71 | 77.8 | Adjuvant (A) | 2020-08-21 | 2020-08-30 | CHOP - 21 days | null | N | CAP + RT | 101230888 |
| 20066525 | 20157610 | 1.57 | 59 | null | 2018-12-11 | 2018-12-13 | Cetuximab + OXALIPLATIN + RALTITREXED | 02 | null | ABEMACICLIB + FULVESTRANT | 101677664 |
| 20066571 | 20157611 | 1.76 | 104 | Palliative (P) | 2021-12-08 | 2021-12-14 | Rituximab (Maintenance) | 02 | N | ECARBOX | 100904687 |
| 20066628 | 20157612 | 1.77 | 74.8 | Palliative (P) | 2020-08-29 | 2020-09-06 | Carboplatin + Pembrolizumab + Pemetrexed | 2 | null | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 101383090 |
| 20066854 | 20157613 | 1.82 | 50 | Palliative (P) | 2019-01-28 | 2019-02-18 | INTERAACT trial | N | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100535303 |
| 20067069 | 20157614 | 1.71 | 61 | Palliative (P) | 2020-01-03 | 2020-01-04 | Durvalumab | 02 | null | CHOP R | 100962822 |
| 20067237 | 20157616 | 1.55 | 67.8 | Curative (C) | 2021-05-16 | 2021-06-07 | ACELARATE Trial | 02 | N | PHITT D CARBOPLATIN/DOXORUBICIN | 101838553 |
| 20067530 | 20157618 | 1.8 | 72.3 | Palliative (P) | 2016-09-18 | 2016-09-21 | STS Non-Rhabdo EpSSG 2005 Vcy | 02 | null | MPV | 100004687 |
| 20067942 | 20157619 | 1.75 | 117.5 | null | 2022-05-05 | 2022-05-05 | GDP | 02 | null | PHITT D SIOPEL-4 (A1, A2, A3) | 101215072 |
| 20067991 | 20157620 | 1.58 | 63 | null | 2015-12-25 | 2016-05-27 | Cyclophosphamide oral | 02 | N | TEYSUNO | 100025544 |
| 20068083 | 20157621 | null | 79.8 | Curative (C) | 2022-03-30 | 2022-04-14 | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 02 | null | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 100227267 |
| 20068143 | 20157622 | 1.54 | 74.1 | Curative (C) | 2020-02-20 | 2021-03-23 | ATEZOLIZUMAB + NAB PACLITAXEL | 02 | N | SCOPE2 TRIAL | 101311949 |
| 20068190 | 20157623 | 1.78 | 83.9 | Palliative (P) | 2021-08-04 | 2022-05-19 | Capital Trial | 01 | N | GO2 TRIAL | 100553853 |
| 20068282 | 20157624 | 1.79 | 57 | Curative (C) | null | 2019-03-28 | PEMBROLIZUMAB + PEMETREXED | 2 | Y | NB RELAPSED IRINOTECAN AND TEMOZOLOMIDE | 101332822 |
| 20068492 | 20157625 | 1.65 | 70.1 | null | 2019-07-16 | 2019-07-16 | Rituximab | 02 | N | TOPOTECAN | 100033086 |
| 20069008 | 20157626 | null | 93.2 | null | 2022-05-12 | 2022-05-21 | CHOP R - 21 days | 02 | N | CARBOPLATIN + PEMETREXED | 101602400 |
| 20069155 | 20157627 | 1.81 | 51.3 | null | 2020-07-29 | 2020-08-05 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | null | null | SCOPE2 TRIAL | 101117936 |
| 20069198 | 20157628 | 1.8 | 77.8 | Curative (C) | null | 2019-01-22 | AFATINIB | 01 | N | PHITT D SIOPEL-4 (A1, A2, A3) | 100278818 |